메뉴 건너뛰기




Volumn 47, Issue 2, 2015, Pages 100-105

Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future

Author keywords

Idiopathic pulmonary fibrosis; N acetylcysteine; Nintedanib; Pirfenidone; Prednisone

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; FG 3019; FRESOLIMUMAB; GAMMA INTERFERON; INTERLEUKIN 13; LEBRIKIZUMAB; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NINTEDANIB; PIRFENIDONE; PREDNISONE; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SILDENAFIL; SIMTUZUMAB; TANZISERTIB; THALIDOMIDE; TRALOKINUMAB; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

EID: 84928137999     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.991751     Document Type: Review
Times cited : (26)

References (89)
  • 3
    • 79952717349 scopus 로고    scopus 로고
    • An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management
    • Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788-824.
    • (2011) Am J Respir Crit Care Med. , vol.183 , pp. 788-824
    • Raghu, G.1    Collard, H.R.2    Egan, J.J.3    Martinez, F.J.4    Behr, J.5    Brown, K.K.6
  • 4
    • 85008987259 scopus 로고    scopus 로고
    • This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001
    • American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002; 165: 277-304.
    • (2002) Am J Respir Crit Care Med. , vol.165 , pp. 277-304
  • 6
    • 77957229065 scopus 로고    scopus 로고
    • The registry of the international society for heart and lung transplantation: Twenty-seventh official adult lung and heart-lung transplant report-2010
    • Christie JD, Edwards LB, Kucheryavaya AY, Aurora P, Dobbels F, Kirk R, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant. 2010; 29: 1104-18.
    • (2010) J Heart Lung Transplant. , vol.29 , pp. 1104-1118
    • Christie, J.D.1    Edwards, L.B.2    Kucheryavaya, A.Y.3    Aurora, P.4    Dobbels, F.5    Kirk, R.6
  • 8
    • 0034011982 scopus 로고    scopus 로고
    • Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)
    • American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161(2 Pt 1): 646-64.
    • (2000) Am J Respir Crit Care Med. , vol.161 , Issue.2 , pp. 646-664
  • 9
    • 79953728756 scopus 로고    scopus 로고
    • Novel therapeutic approaches for pulmonary fibrosis
    • Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol. 2011; 163: 141-72.
    • (2011) Br J Pharmacol. , vol.163 , pp. 141-172
    • Datta, A.1    Scotton, C.J.2    Chambers, R.C.3
  • 10
    • 79951844263 scopus 로고    scopus 로고
    • Clinical course and prediction of survival in idiopathic pulmonary fibrosis
    • Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 183: 431-40.
    • (2011) Am J Respir Crit Care Med. , vol.183 , pp. 431-440
    • Ley, B.1    Collard, H.R.2    King, T.E.3
  • 11
    • 67650349068 scopus 로고    scopus 로고
    • Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebo-controlled trial
    • King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009; 374: 222-8.
    • (2009) Lancet , vol.374 , pp. 222-228
    • King, T.E.1    Albera, C.2    Bradford, W.Z.3    Costabel, U.4    Hormel, P.5    Lancaster, L.6
  • 14
    • 0026389762 scopus 로고
    • Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind, randomized, placebocontrolled clinical trial
    • Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebocontrolled clinical trial. Am Rev Respir Dis. 1991; 144: 291-6.
    • (1991) Am Rev Respir Dis. , vol.144 , pp. 291-296
    • Raghu, G.1    Depaso, W.J.2    Cain, K.3    Hammar, S.P.4    Wetzel, C.E.5    Dreis, D.F.6
  • 15
  • 16
    • 0029951895 scopus 로고    scopus 로고
    • Serum indicators of free radical activity in idiopathic pulmonary fibrosis
    • Jack CI, Jackson MJ, Johnston ID, Hind CR. Serum indicators of free radical activity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1996; 153(6 Pt 1): 1918-23.
    • (1996) Am J Respir Crit Care Med. , vol.153 , Issue.6 , pp. 1918-1923
    • Jack, C.I.1    Jackson, M.J.2    Johnston, I.D.3    Hind, C.R.4
  • 18
    • 0025886739 scopus 로고
    • Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis
    • Borok Z, Buhl R, Grimes GJ, Bokser AD, Hubbard RC, Holroyd KJ, et al. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet. 1991; 338: 215-16.
    • (1991) Lancet , vol.338 , pp. 215-216
    • Borok, Z.1    Buhl, R.2    Grimes, G.J.3    Bokser, A.D.4    Hubbard, R.C.5    Holroyd, K.J.6
  • 19
    • 0036014536 scopus 로고    scopus 로고
    • Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: Effects of N-acetylcysteine
    • Behr J, Degenkolb B, Krombach F, Vogelmeier C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J. 2002; 19: 906-11.
    • (2002) Eur Respir J. , vol.19 , pp. 906-911
    • Behr, J.1    Degenkolb, B.2    Krombach, F.3    Vogelmeier, C.4
  • 22
    • 84901746607 scopus 로고    scopus 로고
    • Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis
    • Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez F J, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2093-101.
    • (2014) N Engl J Med. , vol.370 , pp. 2093-2101
    • Martinez, F.J.1    De Andrade, J.A.2    Anstrom, K.J.3    King, T.E.4    Raghu, G.5
  • 23
    • 0037338580 scopus 로고    scopus 로고
    • Interferon-gamma reduces interleukin-4- and interleukin-13-augmented transforming growth factor-beta2 production in human bronchial epithelial cells by targeting Smads
    • Wen FQ, Liu XD, Terasaki Y, Fang QH, Kobayashi T, Abe S, et al. Interferon-gamma reduces interleukin-4- and interleukin-13-augmented transforming growth factor-beta2 production in human bronchial epithelial cells by targeting Smads. Chest. 2003; 123(3 Suppl): 372S- 3S.
    • (2003) Chest , vol.123 , Issue.3 , pp. 372S-3S
    • Wen, F.Q.1    Liu, X.D.2    Terasaki, Y.3    Fang, Q.H.4    Kobayashi, T.5    Abe, S.6
  • 24
    • 0345824715 scopus 로고    scopus 로고
    • A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
    • Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004; 350: 125-33.
    • (2004) N Engl J Med. , vol.350 , pp. 125-133
    • Raghu, G.1    Brown, K.K.2    Bradford, W.Z.3    Starko, K.4    Noble, P.W.5    Schwartz, D.A.6
  • 26
    • 0027213101 scopus 로고
    • Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis
    • Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet. 1993; 341: 1550-4.
    • (1993) Lancet , vol.341 , pp. 1550-1554
    • Giaid, A.1    Michel, R.P.2    Stewart, D.J.3    Sheppard, M.4    Corrin, B.5    Hamid, Q.6
  • 27
    • 0023765634 scopus 로고
    • Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells
    • Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988; 238: 249-52.
    • (1988) FEBS Lett. , vol.238 , pp. 249-252
    • Komuro, I.1    Kurihara, H.2    Sugiyama, T.3    Yoshizumi, M.4    Takaku, F.5    Yazaki, Y.6
  • 28
    • 0031629184 scopus 로고    scopus 로고
    • Endothelins: Effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts
    • Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol. 1998; 31(Suppl 1): S360-3.
    • (1998) J Cardiovasc Pharmacol. , vol.31 , pp. S360-S363
    • Xu, S.1    Denton, C.P.2    Holmes, A.3    Dashwood, M.R.4    Abraham, D.J.5    Black, C.M.6
  • 29
    • 0032825924 scopus 로고    scopus 로고
    • Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases
    • Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, Kivity S, et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol. 1999; 21: 759-75.
    • (1999) Int J Immunopharmacol. , vol.21 , pp. 759-775
    • Shahar, I.1    Fireman, E.2    Topilsky, M.3    Grief, J.4    Schwarz, Y.5    Kivity, S.6
  • 31
    • 0030755489 scopus 로고    scopus 로고
    • Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist
    • Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med. 1997; 156(2 Pt 1): 600-8.
    • (1997) Am J Respir Crit Care Med. , vol.156 , Issue.2 , pp. 600-608
    • Park, S.H.1    Saleh, D.2    Giaid, A.3    Michel, R.P.4
  • 34
    • 53149152248 scopus 로고    scopus 로고
    • Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis
    • Nathan SD, Shlobin OA, Ahmad S, Koch J, Barnett SD, Ad N, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration. 2008; 76: 288-94.
    • (2008) Respiration. , vol.76 , pp. 288-294
    • Nathan, S.D.1    Shlobin, O.A.2    Ahmad, S.3    Koch, J.4    Barnett, S.D.5    Ad, N.6
  • 35
    • 58349114626 scopus 로고    scopus 로고
    • Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis
    • Glaser S, Noga O, Koch B, Opitz CF, Schmidt B, Temmesfeld B, et al. Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med. 2009; 103: 317-24.
    • (2009) Respir Med. , vol.103 , pp. 317-324
    • Glaser, S.1    Noga, O.2    Koch, B.3    Opitz, C.F.4    Schmidt, B.5    Temmesfeld, B.6
  • 36
    • 33947386257 scopus 로고    scopus 로고
    • Sildenafil improves walk distance in idiopathic pulmonary fibrosis
    • Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131: 897-9.
    • (2007) Chest , vol.131 , pp. 897-899
    • Collard, H.R.1    Anstrom, K.J.2    Schwarz, M.I.3    Zisman, D.A.4
  • 37
    • 0037152092 scopus 로고    scopus 로고
    • Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial
    • Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360: 895-900.
    • (2002) Lancet , vol.360 , pp. 895-900
    • Ghofrani, H.A.1    Wiedemann, R.2    Rose, F.3    Schermuly, R.T.4    Olschewski, H.5    Weissmann, N.6
  • 39
    • 58149234456 scopus 로고    scopus 로고
    • Protein kinase inhibitors in the treatment of pulmonary fibrosis
    • Garneau-Tsodikova S, Thannickal VJ. Protein kinase inhibitors in the treatment of pulmonary fibrosis. Curr Med Chem. 2008; 15: 2632-40.
    • (2008) Curr Med Chem. , vol.15 , pp. 2632-2640
    • Garneau-Tsodikova, S.1    Thannickal, V.J.2
  • 40
    • 0028916492 scopus 로고
    • Plateletderived growth factor isoforms PDGF-AA, -AB and -BB exert specific effects on collagen gene expression and mitotic activity of cultured human wound fibroblasts
    • Lepisto J, Peltonen J, Vaha-Kreula M, Niinikoski J, Laato M. Plateletderived growth factor isoforms PDGF-AA, -AB and -BB exert specific effects on collagen gene expression and mitotic activity of cultured human wound fibroblasts. Biochem Biophys Res Commun. 1995; 209: 393-9.
    • (1995) Biochem Biophys Res Commun. , vol.209 , pp. 393-399
    • Lepisto, J.1    Peltonen, J.2    Vaha-Kreula, M.3    Niinikoski, J.4    Laato, M.5
  • 44
    • 77958165170 scopus 로고    scopus 로고
    • Pirfenidone in idiopathic pulmonary fibrosis
    • Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc). 2010; 46: 473-82.
    • (2010) Drugs Today (Barc) , vol.46 , pp. 473-482
    • Maher, T.M.1
  • 45
    • 0032842405 scopus 로고    scopus 로고
    • Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis
    • Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999; 291: 367-73.
    • (1999) J Pharmacol Exp Ther. , vol.291 , pp. 367-373
    • Iyer, S.N.1    Gurujeyalakshmi, G.2    Giri, S.N.3
  • 46
    • 48149113955 scopus 로고    scopus 로고
    • Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
    • Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008; 590: 400-8.
    • (2008) Eur J Pharmacol. , vol.590 , pp. 400-408
    • Oku, H.1    Shimizu, T.2    Kawabata, T.3    Nagira, M.4    Hikita, I.5    Ueyama, A.6
  • 47
    • 0036844834 scopus 로고    scopus 로고
    • Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production
    • Di Sario A, Bendia E, Svegliati Baroni G, Ridolfi F, Casini A, Ceni E, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol. 2002; 37: 584-91.
    • (2002) J Hepatol. , vol.37 , pp. 584-591
    • Di Sario, A.1    Bendia, E.2    Svegliati Baroni, G.3    Ridolfi, F.4    Casini, A.5    Ceni, E.6
  • 48
    • 0032926937 scopus 로고    scopus 로고
    • Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label Phase II study
    • Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999; 159(4 Pt 1): 1061-9.
    • (1999) Am J Respir Crit Care Med. , vol.159 , Issue.4 , pp. 1061-1069
    • Raghu, G.1    Johnson, W.C.2    Lockhart, D.3    Mageto, Y.4
  • 49
    • 20944434994 scopus 로고    scopus 로고
    • Doubleblind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
    • Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Doubleblind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171: 1040-7.
    • (2005) Am J Respir Crit Care Med. , vol.171 , pp. 1040-1047
    • Azuma, A.1    Nukiwa, T.2    Tsuboi, E.3    Suga, M.4    Abe, S.5    Nakata, K.6
  • 51
    • 79956341531 scopus 로고    scopus 로고
    • Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials
    • Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377: 1760-9.
    • (2011) Lancet , vol.377 , pp. 1760-1769
    • Noble, P.W.1    Albera, C.2    Bradford, W.Z.3    Costabel, U.4    Glassberg, M.K.5    Kardatzke, D.6
  • 53
    • 84903166926 scopus 로고    scopus 로고
    • Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
    • Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014; 19: 740-7.
    • (2014) Respirology. , vol.19 , pp. 740-747
    • Valeyre, D.1    Albera, C.2    Bradford, W.Z.3    Costabel, U.4    King, T.E.5    Leff, J.A.6
  • 54
    • 84900818404 scopus 로고    scopus 로고
    • Pirfenidone in idiopathic pulmonary fibrosis: Expert panel discussion on the management of drug-related adverse events
    • Costabel U, Bendstrup E, Cottin V, Dewint P, Egan JJ, Ferguson J, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014; 31: 375-91.
    • (2014) Adv Ther. , vol.31 , pp. 375-391
    • Costabel, U.1    Bendstrup, E.2    Cottin, V.3    Dewint, P.4    Egan, J.J.5    Ferguson, J.6
  • 56
    • 34248355179 scopus 로고    scopus 로고
    • A ngiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: Autocrine mechanisms in myofibroblasts and macrophages
    • Uhal B D, Kim J K, Li X, M olina-Molina M. A ngiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr Pharm Des. 2007; 13: 1247-56.
    • (2007) Curr Pharm Des. , vol.13 , pp. 1247-1256
    • Uhal, B.D.1    Kim, J.K.2    Li, X.3    Olina-Molina, M.M.4
  • 57
    • 0033862955 scopus 로고    scopus 로고
    • Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor
    • Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol. 2000; 279: L143-51.
    • (2000) Am J Physiol Lung Cell Mol Physiol. , vol.279 , pp. L143-L151
    • Wang, R.1    Ibarra-Sunga, O.2    Verlinski, L.3    Pick, R.4    Uhal, B.D.5
  • 58
    • 0346057802 scopus 로고    scopus 로고
    • Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist
    • Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax. 2004; 59: 31-8.
    • (2004) Thorax , vol.59 , pp. 31-38
    • Otsuka, M.1    Takahashi, H.2    Shiratori, M.3    Chiba, H.4    Abe, S.5
  • 60
    • 4143091523 scopus 로고    scopus 로고
    • Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis
    • Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest. 2004; 126: 438-46.
    • (2004) Chest , vol.126 , pp. 438-446
    • Nadrous, H.F.1    Ryu, J.H.2    Douglas, W.W.3    Decker, P.A.4    Olson, E.J.5
  • 61
    • 40349098060 scopus 로고    scopus 로고
    • Procoagulant signalling mechanisms in lung inflammation and fibrosis: Novel opportunities for pharmacological intervention?
    • Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol. 2008; 153(Suppl 1): S367-78.
    • (2008) Br J Pharmacol. , vol.153 , pp. S367-S378
    • Chambers, R.C.1
  • 63
    • 0034795622 scopus 로고    scopus 로고
    • Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis
    • Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol. 2001; 159: 1383-95.
    • (2001) Am J Pathol. , vol.159 , pp. 1383-1395
    • Howell, D.C.1    Goldsack, N.R.2    Marshall, R.P.3    McAnulty, R.J.4    Starke, R.5    Purdy, G.6
  • 64
    • 70349422341 scopus 로고    scopus 로고
    • Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury
    • Scotton C J, Krupiczojc M A, Konigshoff M, Mercer PF, Lee YC, Kaminski N, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest. 2009; 119: 2550-63.
    • (2009) J Clin Invest. , vol.119 , pp. 2550-2563
    • Scotton, C.J.1    Krupiczojc, M.A.2    Konigshoff, M.3    Mercer, P.F.4    Lee, Y.C.5    Kaminski, N.6
  • 68
    • 0027231698 scopus 로고
    • Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis
    • Nash JR, McLaughlin PJ, Butcher D, Corrin B. Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis. Histopathology. 1993; 22: 343-7.
    • (1993) Histopathology. , vol.22 , pp. 343-347
    • Nash, J.R.1    McLaughlin, P.J.2    Butcher, D.3    Corrin, B.4
  • 69
    • 0027724235 scopus 로고
    • Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis
    • Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol. 1993; 143: 651-5.
    • (1993) Am J Pathol. , vol.143 , pp. 651-655
    • Piguet, P.F.1    Ribaux, C.2    Karpuz, V.3    Grau, G.E.4    Kapanci, Y.5
  • 70
    • 0032084906 scopus 로고    scopus 로고
    • Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis
    • Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Muller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med. 1998; 46: 223-31.
    • (1998) J Investig Med. , vol.46 , pp. 223-231
    • Ziegenhagen, M.W.1    Schrum, S.2    Zissel, G.3    Zipfel, P.F.4    Schlaak, M.5    Muller-Quernheim, J.6
  • 71
    • 0024414604 scopus 로고
    • Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis
    • Piguet P F, Collart M A, Grau G E, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989; 170: 655-63.
    • (1989) J Exp Med. , vol.170 , pp. 655-663
    • Piguet, P.F.1    Collart, M.A.2    Grau, G.E.3    Kapanci, Y.4    Vassalli, P.5
  • 72
    • 0031568010 scopus 로고    scopus 로고
    • TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis
    • Zhang K, Gharaee-Kermani M, McGarry B, Remick D, Phan SH. TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol. 1997; 158: 954-9.
    • (1997) J Immunol. , vol.158 , pp. 954-959
    • Zhang, K.1    Gharaee-Kermani, M.2    McGarry, B.3    Remick, D.4    Phan, S.H.5
  • 73
    • 7844226301 scopus 로고    scopus 로고
    • Expression of TNF and the necessity of TNF receptors in bleomycininduced lung injury in mice
    • Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, et al. Expression of TNF and the necessity of TNF receptors in bleomycininduced lung injury in mice. Exp Lung Res. 1998; 24: 721-43.
    • (1998) Exp Lung Res. , vol.24 , pp. 721-743
    • Ortiz, L.A.1    Lasky, J.2    Hamilton, R.F.3    Holian, A.4    Hoyle, G.W.5    Banks, W.6
  • 75
    • 0032813516 scopus 로고    scopus 로고
    • On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease
    • Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev. 1999; 169: 175-94.
    • (1999) Immunol Rev. , vol.169 , pp. 175-194
    • Kollias, G.1    Douni, E.2    Kassiotis, G.3    Kontoyiannis, D.4
  • 76
  • 78
    • 0032100486 scopus 로고    scopus 로고
    • Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset
    • Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset. J Exp Med. 1998; 187: 1885-92.
    • (1998) J Exp Med. , vol.187 , pp. 1885-1892
    • Haslett, P.A.1    Corral, L.G.2    Albert, M.3    Kaplan, G.4
  • 80
    • 84868327008 scopus 로고    scopus 로고
    • Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: A randomized trial
    • Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012; 157: 398-406.
    • (2012) Ann Intern Med. , vol.157 , pp. 398-406
    • Horton, M.R.1    Santopietro, V.2    Mathew, L.3    Horton, K.M.4    Polito, A.J.5    Liu, M.C.6
  • 82
    • 77956425361 scopus 로고    scopus 로고
    • Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment
    • Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010; 16: 1009-17.
    • (2010) Nat Med. , vol.16 , pp. 1009-1017
    • Barry-Hamilton, V.1    Spangler, R.2    Marshall, D.3    McCauley, S.4    Rodriguez, H.M.5    Oyasu, M.6
  • 85
    • 84975326256 scopus 로고    scopus 로고
    • Phase 2 trial of FG-109, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): Preliminary safety and efficacy results
    • Raghu G, Scholand MB, de Andrade J, Lancaster L, Goldin MB, Porter S, et al. Phase 2 trial of FG-109, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): preliminary safety and efficacy results. Eur Respir J. 2012; 40: Suppl. 56, 511s.
    • (2012) Eur Respir J. , vol.40 , pp. 511S
    • Raghu, G.1    Scholand, M.B.2    De Andrade, J.3    Lancaster, L.4    Goldin, M.B.5    Porter, S.6
  • 86
    • 84928126872 scopus 로고    scopus 로고
    • Predictors of mortality in idiopathic pulmonary fibrosis: Results from 72 week phase II study of CNTO888 (Carlumab)
    • Raghu G, Agarwal P, Mack M, Martinez F, Brown K, Costabel U, et al. Predictors of mortality in idiopathic pulmonary fibrosis: results from 72 week phase II study of CNTO888 (Carlumab). Am J Respir Crit Care Med. 2013; 187: A3377.
    • (2013) Am J Respir Crit Care Med. , vol.187 , pp. A3377
    • Raghu, G.1    Agarwal, P.2    MacK, M.3    Martinez, F.4    Brown, K.5    Costabel, U.6
  • 87
    • 0036840030 scopus 로고    scopus 로고
    • MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis
    • Yoshida K, Kuwano K, Hagimoto N, Watanabe K, Matsuba T, Fujita M, et al. MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol. 2002; 198: 388-96.
    • (2002) J Pathol. , vol.198 , pp. 388-396
    • Yoshida, K.1    Kuwano, K.2    Hagimoto, N.3    Watanabe, K.4    Matsuba, T.5    Fujita, M.6
  • 88
    • 2142646426 scopus 로고    scopus 로고
    • T GF-beta signaling and the fibrotic response
    • Leask A, Abraham D J. T GF-beta signaling and the fibrotic response. FASEB J. 2004; 18: 816-27.
    • (2004) FASEB J. , vol.18 , pp. 816-827
    • Leask, A.1    Abraham, D.J.2
  • 89
    • 38049002642 scopus 로고    scopus 로고
    • Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation
    • Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008; 177: 56-65.
    • (2008) Am J Respir Crit Care Med. , vol.177 , pp. 56-65
    • Horan, G.S.1    Wood, S.2    Ona, V.3    Li, D.J.4    Lukashev, M.E.5    Weinreb, P.H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.